Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology
4 个月之前
marketscreener.com
Tyler Reagan on Patient Engagement & Advocacy for CAH Community | Neurocrine Biosciences posted on the topic | LinkedIn
Tyler Reagan on Patient Engagement & Advocacy for CAH Community | Neurocrine Biosciences posted on the topic | LinkedIn
已浏览 9.2万 次2 个月之前
linkedin.com
Neurocrine Starts Phase 1 Trial of NBIP-01435 to Potentially Treat Congenital Adrenal Hyperplasia
Neurocrine Starts Phase 1 Trial of NBIP-01435 to Potentially Treat Congenital Adrenal Hyperplasia
10 个月之前
marketscreener.com
Neurocrine Biosciences TV Spot, 'Talk About TD'
0:59
Neurocrine Biosciences TV Spot, 'Talk About TD'
2020年2月5日
iSpot.tv
Flowing Stories | Ingrezza | Neurocrine Biosciences | Healthy Ads
Flowing Stories | Ingrezza | Neurocrine Biosciences | Healthy Ads
2 周前
linkedin.com
Neurocrine publie un solide premier trimestre porté par ses traitements phares, selon Morgan Stanley
Neurocrine publie un solide premier trimestre porté par ses traitements phares, selon Morgan Stanley
1 周前
zonebourse.com
Neurocrine breidt uit naar metabole ziekten met overname Soleno van 2,9 miljard dollar
Neurocrine breidt uit naar metabole ziekten met overname Soleno van 2,9 miljard dollar
1 个月前
marketscreener.com
Neurocrine Biosciences, Inc.: Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA (valbenazine) Capsules in Older Adults with Tardive ...
10 个月之前
finanznachrichten.de
Neurocrine Biosciences, Inc. dévoile de nouvelles données sur trois ans confirmant les bénéfices cliniques durables et le profil de sécurité établi d'INGREZZA (Valbenazine) dans la chorée de Huntington
7 个月之前
zonebourse.com
Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout
1 个月前
marketscreener.com
0:13
Neurocrine Biosciences just announced a $2.9Billion all cash acquisition of Soleno Therapeutics. The deal terms call for $53 per share, which is a 34% premium over current pricing. Soleno’s VYKAT… | Ξl Boyd
1 周前
linkedin.com
3:10
Neurocrine crushes the IBB
2015年9月18日
CNBC
Neurocrine Biosciences Preliminary Full-Year INGREZZA Net Product Sales Up 32%
2021年1月8日
nasdaq.com
Is Neurocrine Biosciences (NBIX) a Smart Long-term Buy?
2020年12月11日
insidermonkey.com
We’re excited to announce the initiation of our Phase 1 study of NBIP- 2118, an investigational corticotropin-releasing factor type 2 receptor (CRF₂) agonist peptide and potential first-in-class… | Neurocrine Biosciences
已浏览 1 次1 周前
linkedin.com
Neurocrine: Q1 Earnings Snapshot
1 周前
kgw.comAssociated Press
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
4 天之前
wyomingnews.com
Biotech Leader Neurocrine Biosciences Stock Fights To Regain Buy Point At Key Resistance Level
5 个月之前
investors.com
Neurocrine Snags Early Approval For A First-In-Decades Drug
2024年12月13日
investors.com
Today, during Tardive Dyskinesia Awareness Week, we shared findings from a new survey of U.S. adults that underscore the significant impact that tardive dyskinesia (TD) has on a patient’s ability to… | Neurocrine Biosciences
1 周前
linkedin.com
Was The Smart Money Wrong About Neurocrine Biosciences, Inc. (NBIX)?
2020年11月4日
insidermonkey.com
Neurocrine Biosciences | LinkedIn
2023年1月31日
linkedin.com
2:48
Neuroendocrine in biology
2024年6月5日
humix.com
Interactive Chart
4 个月之前
zacks.com
37:48
Neurocrine Biosciences @ JPM 2026 第44届摩根大通医疗保健会议
已浏览 51 次3 个月之前
bilibilibili_42520431755
Neurocrine Biosciences Parkinson's Drug Cleared by FDA
2020年4月27日
thestreet.com
Neurocrine Biosciences Snags U.S. Approval for Movement Disorder Drug
2019年12月6日
thestreet.com
33:58
【Neuron】空间记忆依赖下丘脑 hypocretin 系统提升内嗅皮层中部 γ 振荡
已浏览 389 次6 个月之前
bilibiliMiao_Lab_PKU
展开